Estudio a largo plazo (más de 10 años de evolución), de las complicaciones de las artroplastias trapecio-metacarpianas de tipo ARPE

Producción CientíficaResumen: Objetivo: La artrosis trapecio-metacarpiana es una patología incapacitante, que produce dolor, disminución de la fuerza, pérdida de destreza en la pinza y limitación de la movilidad del pulgar. Cuando fracasa el tratamiento médico se pueden realizar diferentes técnicas quirúrgicas. Las prótesis totales de la articulación representan una de ellas. Desde mayo de 1999 hasta abril de 2004 se realizaron, de forma consecutiva, un total de 116 prótesis totales de la articulación trapecio-metacarpiana en 103 pacientes que padecían artrosis, utilizando la prótesis no cementada y no constreñida tipo ARPE® (Biomet Spain Orthopaedics SL, Valencia). Se presentan en este estudio los resultados de la revisión clínica, funcional y radiológica de los pacientes revisados durante 10 años de evolución. Material y Método: Los análisis de supervivencia fueron realizados mediante el método de Kaplan-Meier. De los 103 pacientes, 6 fueron excluidos y 97 pacientes, con 109 prótesis acabaron el estudio. Resultados: En la revisión de los 10 años de evolución, 102 (93,6%) eran prótesis funcionales y 7 (6,4%) prótesis eran consideradas prótesis fallidas (3 retiradas por aflojamiento, 3 luxaciones y 1 subluxación y dolor). La probabilidad de supervivencia de Kaplan–Meier fue de 94.1% [CI95% (90.4%,98.8%)]. Radiográficamente, 88 (86,3%) de las prótesis consideradas funcionales no mostraron evidencia de alteraciones del implante y 14 (13,7%) mostraron cambios radiográficos que eran compatibles con la funcionalidad del implante. Se presenta en detalle el estudio de las complicaciones que han existido, con las posibles soluciones en las cirugías de revisión. Conclusión: La prótesis total de ARPE® ofrece una alternativa de tratamiento segura y fiable en pacientes con artrosis trapecio-metacarpiana grado III y algunos de grado IV con buen capital óseo, sobre todo, en el trapecio. La mayoría de las complicaciones aparecen por defectos de indicación o por defectos de la técnica quirúrgica y se pueden resolver con recambio protésico o con trapecectomía dependiendo de las circunstancias del implante y del paciente

Influence of the emotional alterations in the arterial stiffness index and cardiovascular risk of pre-hypertensive patients

Purpose: To determine the influence of emotional alterations in the arterial stiffness index and cardiovascular risk of pre-hypertensive patients.Methods: A cross-sectional study was carried out in 48 pre-hypertensive patients. Emotional alterations, global cardiovascular risk and arterial stiffness index were evaluated. The PPG technique was used to record the arterial pulse wave in the first finger of the lower right limb, using the ANGIODIN® digital plethysmograph.Results: Pre-hypertensive patients with emotional alterations had major Weight, Body Mass Index, systolic blood pressure, diastolic blood pressure and arterial stiffness index with respect to patients who did not find emotional alterations. In pre-hypertensive patients, 58.3% presented a positive Cornell test, 39.6% of them female, and 18.8% male. There was a significant relationship (p<0.001) between the presence of emotional disturbances and moderate cardiovascular risk.Conclusions: Emotional alterations in pre-hypertensive patients is associated with an increase in arterial stiffness and an increased global cardiovascular risk

Scientometric Analysis of Hiking Tourism and Its Relevance for Wellbeing and Knowledge Management

Hiking is a sports activity that takes place in the natural environment. From the point of view of well-being, it is an aerobic activity that prevents and improves cardiovascular diseases. According to data provided by the United Nations, within the framework of the International Year of Mountains, mountain tourism represents around 15% to 20% of total world tourism revenue. This approach aims to critically analyze the scientific production on trail tourism (HT) with contributions from authors from around the world from 1991 to 2022, in order to respond to the connection between this research, knowledge management and the sustainable development of the industry. Key knowledge contributions are examined using a scientometric approach as a method (spatial, production, impact, and relational) based on registry data stored in the Web of Science (JCR and ESCI). Regarding the results, there has been an increase in scientific production in the last decade, which is manifested in the quality of the publications

The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE E4 Non-carriers

An ancestral inversion of 900 kb on chromosome 17q21, which includes the microtubule-associated protein tau (MAPT) gene, defines two haplotype clades in Caucasians (H1 and H2). The H1 haplotype has been linked inconsistently with AD. In a previous study, we showed that an SNP tagging this haplotype (rs1800547) was associated with AD risk in a large population from the Dementia Genetics Spanish Consortium (DEGESCO) including 4435 cases and 6147 controls. The association was mainly driven by individuals that were non-carriers of the APOE ?4 allele. Our aim was to replicate our previous findings in an independent sample of 4124 AD cases and 3290 controls from Spain (GR@ACE project) and to analyze the effect of the H1 sub-haplotype structure on the risk of AD. The H1 haplotype was associated with AD risk (OR = 1.12; p = 0.0025). Stratification analysis showed that this association was mainly driven by the APOE ?4 non-carriers (OR = 1.15; p = 0.0022). Pooled analysis of both Spanish datasets (n = 17,996) showed that the highest AD risk related to the MAPT H1/H2 haplotype was in those individuals that were the oldest [third tertile (>77 years)] and did not carry APOE ?4 allele (p = 0.001). We did not find a significant association between H1 sub-haplotypes and AD. H1c was nominally associated but lost statistical significance after adjusting by population sub-structure. Our results are consistent with the hypothesis that genetic variants linked to the MAPT H1/H2 are tracking a genuine risk allele for AD. The fact that this association is stronger in APOE ?4 non-carriers partially explains previous controversial results and might be related to a slower alternative causal pathway less dependent on brain amyloid load.ACKNOWLEDGMENTS: The Genome Research at Fundacio ACE/Dementia Genetics Spanish Consortium (GR@ACE/DEGESCO) would like to thank patients and controls who participated in this project. GR@ACE/DEGESCO GWAS program was funded by Grifols SA, Fundacion Bancaria “La Caixa,” and Fundació ACE, Institut Català de Neurociències Aplicades. PS-J and AR have also received support by grant PI16/01861. Accion Estrategica en Salud integrated in the Spanish National ICDCi Plan and financed by Instituto de Salud Carlos III (ISCIII) – Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER – “Una Manera de Hacer Europa”). PS-J was supported by IDIVAL, Instituto de Salud Carlos III [Fondo de Investigacion Sanitario, PI08/0139, PI12/02288, PI16/01652, JPND (DEMTEST PI11/03028)], and the CIBERNED program. We thank Biobanco Valdecilla for their support. LM was supported by Consejería de Salud de la Junta de Andalucía (Grant PI-0001/2017). DEGESCO was also sponsored by the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, Spain). Control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain) and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The genotyping service to generate GR@ACE/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it was supported by grant PT17/0019, of the PE ICDCi 2013–2016, funded by ISCIII and ERDF. GR@ACE/DEGESCO consortia would also like to thank to all researchers contributing to this project

The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

Acute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF. A total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded. Three groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC). Acute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. ClinicalTrials.gov number: NCT03056612. Lay summary: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk

Cirrosis biliar primaria con neumonía organizada secundaria

Resume: Organized pneumonia, previously called bronchiolitis obliterans with organized pneumonia, is an interstitial lung disea- se that belongs to the group of idiopathic interstitial diseases and was first recognized in 1985. Sometimes it is not rela- ted to a specific cause calleing it in that case cryptogenetic, organized pneumonia but is frequently associated with other etiologies that may be infectious, inflammatory, neoplastic or secondary to drugs, it might also be related to extrapul- monary pathology as is the case of our patient in which is associated with a chronic cholestatic liver disease such as primary biliary cirrhosis

Análisis de fase en estudios Gated-SPECT como predictor de mortalidad en pacientes con enfermedad coronaria y función ventricular izquierda deprimida

Resumen: Antecedentes: La enfermedad coronaria es una de las principales causas de morbimortalidad en los países occidentales. En etapas avanzadas de la enfermedad, los procesos de remodelación miocárdica pueden conducir a insuficiencia cardíaca progresiva y disfunción ventricular izquierda. El análisis de fase de los estudios de perfusión miocárdica Gated-SPECT muestra parámetros que han sido caracterizados como marcadores válidos de asincronía ventricular. Objetivo: Evaluar los parámetros del análisis de fase en Gated-SPECT como predictores independientes de mortalidad en pacientes con enfermedad coronaria avanzada e insuficiencia ventricular izquierda. Materiales y método: Estudio retrospectivo de cohortes históricas de 185 pacientes consecutivos (140 hombres; edad media=67,6±12,7 años) a los que, entre enero de 2009 y marzo de 2011, se les hizo estudio isotópico de perfusión miocárdica con estimulación farmacológica con resultado positivo para isquemia/necrosis con FEVI ≤ 55%. Adicionalmente, se les realizó seguimiento medio de 32,4±10,5 meses registrándose la aparición de eventos cardíacos mayores (infarto agudo de miocardio no mortal, ingreso hospitalario y revascularización coronaria tardía) y mortalidad total. Resultados: Durante el seguimiento se registraron eventos mayores en 51 pacientes así como 28 fallecimientos, de los cuales, 82,1% mostró valores alterados de los parámetros de fase: media=141,1°±17,6°; desviación estándar=15,8°±10,1°; ancho de banda=59,1°±36° y FEVI=42,4%±10,8%. El análisis de Cox mostró al ancho de banda como un predictor independiente de muerte, disminuyendo significativamente la supervivencia y aumentando el riesgo de muerte (hazard ratio=2,68; p<0,05). Conclusiones: El ancho de banda en el análisis de fase se comporta como un predictor independiente de muerte en pacientes con miocardiopatía conocida y FEVI deprimida. Abstract: Background: Coronary disease is one of the main causes of morbidity and mortality in western countries. In the advanced stages of the disease the myocardial remodelling processes can lead to progressive heart failure and left ventricular impairment. The phase analysis of Gated-SPECT studies of myocardial perfusion show parameters that have been characterised as valid marker of ventricular asynchrony. Objective: To evaluate the phase analysis parameters in Gated SPECT as independent predictors of mortality in patients with advanced coronary disease and left ventricular failure. Materials and method: A retrospective historic cohort study was conducted on 185 consecutive patients (140 males; mean age = 67.6±12.7 years) on whom, between January 2009 and March 2011, an isotope myocardial perfusion study was carried out with pharmacologic stimulation and with a positive result for ischaemia / necrosis, and with a LVEF ≤ 55%. A mean follow-up of 32.4 ±10.5 months was also performed, recording the appearance of major cardiac events (non-fatal acute myocardial infarctions, hospital admission, delayed coronary revascularisation, and total mortality. Results: Major events were recorded in 51 patients during follow-up. There were also 28 deaths, of which 82.1% showed abnormal values of the phase parameters: media=141.1°±17.6°; standard deviation=15.8°±10.1°; bandwidth=59.1°±36°, and LVEF = 42.4%±10.8%. The Cox analysis showed the bandwidth as an independent predictor of death, significantly reducing the survival and increasing the risk of death (hazard ratio=2.68; P<.05). Conclusions: The bandwidth in the phase analysis behaves as an independent predictive factor in patients with known myocardial disease and an impaired LVEF. Palabras clave: Gated-SPECT, Análisis de fase, Ancho de banda, Predictor de muerte, Pronóstico, Keywords: Gated-SPECT, Phase analysis, Bandwidth, Predictor of death, Prognosi

Revealed results of PCR in 2% agarose gel stained with ethidium bromide under UV.

<p><i>Above:</i> Samples from sixteen tsetse flies submitted to PCR using GmTub primers as DNA quality control. Expected band size ∼380 bp. <i>Middle:</i> Molecular diagnosis of samples from fifteen tsetse flies for <i>T. b. gambiense</i>. First sample corresponds to the one positive tsetse fly. The band at right is the positive control. Expected band size 270 bp. <i>Below:</i> Detection of <i>T. brucei</i> s.l. in animal samples. 5–8 and 11 are positives, 12 is the positive control. Expected band size 177 bp.</p